The first phase I clinical study is expected to begin shortly and will primarily evaluate the safety of Posiphen in healthy volunteers.
“The initiation of the Posiphen phase I program is an important milestone,” stated Dr Gosse Bruinsma, president and CEO of Axonyx. “Alzheimer’s disease devastates millions of individuals worldwide and we remain committed to advancing this potential treatment option that may slow or halt the progression of the disease.”
In preclinical studies, Posiphen has been shown to lower beta amyloid precursor protein ((beta)APP) and beta amyloid (A(beta)) levels in rodents as well as demonstrating a favorable side-effect rate. The presence of toxic beta-amyloid in the brains of Alzheimer’s disease (AD) patients is considered by many experts to be a key pathological event in the causation as well as the progression of AD.